

Subject Index

A

- Adipose tissue metabolism
 - obesity 7: 321–322
- Adrenaline
 - asthma
 - pharmacology 7: 358–360
- β -Adrenergic receptor blocking drugs
 - anaesthesia 7: 396–399
 - tricyclic antidepressant overdose 7: 399–400
- Adrenergic receptors
 - asthma
 - pharmacology 7: 355
- Airways calibre
 - asthma 7: 350–355
- Alcohol
 - causing asthmatic reaction 7: 403–404
- Allergy
 - asthma 7: 348–349
- Allergy testing
 - asthma 7: 385
- Aminophylline, intravenous
 - adverse reactions 7: 404–405
 - overdose 7: 404–405
- Amoxycillin 7: 326–336
 - absorption 7: 328–329
 - antibacterial activity 7: 327
 - with other antibacterial agents 7: 327
 - contra-indications 7: 334
 - distribution 7: 330
 - dosage 7: 335
 - excretion 7: 330
 - gonorrhoea 7: 333–334
 - pharmacokinetics 7: 328–330
 - precautions 7: 335
 - protein binding 7: 330
 - respiratory infections 7: 331–332
 - side effects 7: 334
 - skin and soft tissue infections 7: 334
 - therapeutic efficacy 7: 331–334
 - urinary infections 7: 332–333
- Anaesthesia, general
 - hypertension 7: 396–399
- Antiasthmatic drugs 7: 344–369, 370–390
 - pharmacokinetics 7: 365
 - pharmacology 7: 358–365
 - therapeutic use 7: 370–390
- Antibacterial agents, broad spectrum
 - amoxycillin 7: 326–336
- Antibiotics, broad spectrum
 - amoxycillin 7: 326–336
- Anticonvulsants
 - adverse reactions 7: 394–395
- Antidepressants, tricyclic
 - overdose: cardiovascular abnormalities 7: 323–325
 - overdose: treatment with β -blockade 7: 399–400
- Arrhythmias, cardiac
 - tricyclic antidepressant overdose 7: 323–325
- Asthma
 - acute
 - treatment in children 7: 386–387
 - treatment in adults 7: 376–381
 - adrenergic receptors pharmacology 7: 355
 - airways calibre 7: 350–355
 - allergy 7: 348–349
 - assessment 7: 373–376
 - non-response to previous therapy 7: 373–374
 - physical signs 7: 374–376
 - patient history 7: 373
 - cyclic AMP 7: 355
 - epidemiology 7: 349–350
 - functional changes 7: 347–348
 - humoral factors 7: 350–355
 - bradykinin 7: 351–352
 - histamine 7: 350–351
 - mast cell 7: 353–355
 - prostaglandins 7: 352–353
 - serotonin 7: 353
 - slow reacting substance of anaphylaxis 7: 352
 - maintenance therapy
 - in children 7: 388
 - in adults 7: 381–385

Subject Index

A

- Adipose tissue metabolism
 - obesity 7: 321–322
- Adrenaline
 - asthma
 - pharmacology 7: 358–360
- β -Adrenergic receptor blocking drugs
 - anaesthesia 7: 396–399
 - tricyclic antidepressant overdose 7: 399–400
- Adrenergic receptors
 - asthma
 - pharmacology 7: 355
- Airways calibre
 - asthma 7: 350–355
- Alcohol
 - causing asthmatic reaction 7: 403–404
- Allergy
 - asthma 7: 348–349
- Allergy testing
 - asthma 7: 385
- Aminophylline, intravenous
 - adverse reactions 7: 404–405
 - overdose 7: 404–405
- Amoxycillin 7: 326–336
 - absorption 7: 328–329
 - antibacterial activity 7: 327
 - with other antibacterial agents 7: 327
 - contra-indications 7: 334
 - distribution 7: 330
 - dosage 7: 335
 - excretion 7: 330
 - gonorrhoea 7: 333–334
 - pharmacokinetics 7: 328–330
 - precautions 7: 335
 - protein binding 7: 330
 - respiratory infections 7: 331–332
 - side effects 7: 334
 - skin and soft tissue infections 7: 334
 - therapeutic efficacy 7: 331–334
 - urinary infections 7: 332–333
- Anaesthesia, general
 - hypertension 7: 396–399
- Antiasthmatic drugs 7: 344–369, 370–390
 - pharmacokinetics 7: 365
 - pharmacology 7: 358–365
 - therapeutic use 7: 370–390
- Antibacterial agents, broad spectrum
 - amoxycillin 7: 326–336
- Antibiotics, broad spectrum
 - amoxycillin 7: 326–336
- Anticonvulsants
 - adverse reactions 7: 394–395
- Antidepressants, tricyclic
 - overdose: cardiovascular abnormalities 7: 323–325
 - overdose: treatment with β -blockade 7: 399–400
- Arrhythmias, cardiac
 - tricyclic antidepressant overdose 7: 323–325
- Asthma
 - acute
 - treatment in children 7: 386–387
 - treatment in adults 7: 376–381
 - adrenergic receptors pharmacology 7: 355
 - airways calibre 7: 350–355
 - allergy 7: 348–349
 - assessment 7: 373–376
 - non-response to previous therapy 7: 373–374
 - physical signs 7: 374–376
 - patient history 7: 373
 - cyclic AMP 7: 355
 - epidemiology 7: 349–350
 - functional changes 7: 347–348
 - humoral factors 7: 350–355
 - bradykinin 7: 351–352
 - histamine 7: 350–351
 - mast cell 7: 353–355
 - prostaglandins 7: 352–353
 - serotonin 7: 353
 - slow reacting substance of anaphylaxis 7: 352
 - maintenance therapy
 - in children 7: 388
 - in adults 7: 381–385

- pathology 7: 346-347
 pharmacological mechanisms 7: 350-357
 respiration, control of 7: 355-357
 treatment, aims of 7: 372-373
- B**
- Bradykinin
 asthma 7: 351-352
- Bronchodilators
 asthma
 acute 7: 376-377
 maintenance therapy 7: 381-383
 pharmacology 7: 358-361
- C**
- Chemoreceptors
 asthma
 pharmacology 7: 355-357
- Children
 asthma 7: 385-388
 phenytoin dosage 7: 392-393
- Corticosteroids
 asthma
 acute 7: 377-381
 maintenance therapy 7: 383-384
 pharmacology 7: 363-364
- Corticosteroids: aerosol
 asthma 7: 384
 pharmacology 7: 364
- Corticosteroids, topical
 fluocinonide 7: 337-343
- Corticotrophin
 asthma 7: 384
 pharmacology 7: 364-365
- Cromoglycate sodium
 asthma
 maintenance therapy 7: 383
 pharmacology 7: 362
 asthmatic relation to alcohol 7: 403-404
- Cromolyn, sodium
 see cromoglycate, sodium
- Cyclic AMP
 asthma 7: 355
- D**
- Dermatological vehicles
 see vehicles, dermatological
- Dermatoses, inflammatory
 fluocinonide 7: 342
- Diphenylhydantoin
 see phenytoin
- Drug medication
 non-compliance 7: 391-392
- Drug metabolism
 gold 7: 399
 phenytoin 7: 393-394
- Drug overdosage
 antidepressant, tricyclic
 7: 323-325, 399-400
- Drug reactions, adverse
 aminophylline 7: 404-405
 amoxycillin 7: 334
 anticonvulsants 7: 394-395
 methoxyflurane nephrotoxicity 7: 400-403
 phenytoin 7: 395-396
- Drug regimens
 non-compliance 7: 391-392
- E**
- Eczema
 fluocinonide 7: 339-341
- Ephedrine
 asthma
 pharmacology 7: 360
- F**
- Fluocinonide 7: 337-343
 administration 7: 342
 contra-indications 7: 342
 dermatoses, inflammatory 7: 342
 eczema 7: 339-341
 experimental studies 7: 338-339
 precautions 7: 342
 psoriasis 7: 341
 side-effects 7: 342
 therapeutic trials 7: 339-342
- G**
- Gold
 serum levels 7: 399
- Gonorrhoea
 amoxycillin 7: 333-334
- Gingival hyperplasia
 see hyperplasia, gingival
- H**
- Histamine
 asthma 7: 350-351
- Hyperplasia, gingival
 phenytoin 7: 395-396
- Hypertension
 anaesthesia 7: 396-399
- I**
- Isoprenaline
 asthma
 pharmacology 7: 360
- Isoproterenol
 see isoprenaline

Subject Index

408

M

- Mast cell
 - asthma 7: 353-355
- Metaproterenol
 - see orciprenaline
- Methoxyflurane
 - nephrotoxicity 7: 400-403
- Methylated xanthines
 - see xanthines, methylated

N

- Neonate
 - phenytoin 7: 392-393
- Nephrotoxicity
 - methoxyflurane 7: 400-403

O

- Obesity
 - adipose tissue metabolism 7: 321-322
- Orciprenaline
 - asthma
 - pharmacology 7: 360

P

- Phenytoin
 - adverse reactions 7: 395-396
 - dosage in children 7: 392-393
 - dosage, loading 7: 393-394
 - dosage, maintenance 7: 393-394
 - plasma levels 7: 393-394
- Penicillins
 - amoxycillin 7: 326-336
- Prostaglandins
 - asthma 7: 352-353
- Protein binding
 - amoxycillin 7: 330
- Psoriasis
 - fluocinonide 7: 341
- Pulses paradoxus
 - asthma 7: 375

R

- Respiration, control of
 - asthma 7: 355-357

- Respiratory infections
 - amoxycillin 7: 331-332
- Rheumatoid arthritis
 - gold therapy 7: 399
- Rhonchi
 - asthma 7: 374

S

- Salbutamol
 - asthma
 - pharmacology 7: 361
- Serotonin
 - asthma 7: 353
- Sodium cromoglycate
 - see cromoglycate, sodium
- Spirometric measurements
 - asthma 7: 375
- Sympathomimetic amines
 - asthma
 - pharmacology 7: 358-361

T

- Terbutaline
 - asthma
 - pharmacology 7: 360
- Tricyclic antidepressants
 - see antidepressants, tricyclic

U

- Urinary infections
 - amoxycillin 7: 332-333

V

- Vehicles, dermatological
 - fluocinonide 7: 337-343
- Vehicle formulation
 - fluocinonide - FAPG 7: 338

X

- Xanthines, methylated
 - asthma
 - pharmacology 7: 361-362

